Literature DB >> 35128316

A multidisciplinary approach to prolonged extracorporeal membrane oxygenation for acute respiratory distress syndrome due to coronavirus 2019-case report.

Kathleen Biblowitz1, Megan Mullin1, Lydia McDermott1, Alyssa Sykuta1, Michael Baram1, Hitoshi Hirose1.   

Abstract

Patients with novel coronavirus 2019 (COVID-19) may develop acute respiratory distress syndrome (ARDS) and require extracorporeal membrane oxygenation (ECMO) support. Currently there is no specific treatment for COVID-19 available; thus, for patients with severe ARDS, the respiratory condition needs to improve while on ECMO support. Here we present a multidisciplinary team approach to the care of a patient with COVID-related ARDS requiring three months of veno-venous (VV) ECMO which lead to recovery. A 35-year-old male was transferred to us with ARDS due to COVID-19 infection with a lactate 13.7 mmol/L and an arterial-blood gas oxygenation of 75 mmHg on maximum ventilator settings. He was placed on VV ECMO during which he developed pneumonia, bacteremia, and pneumothoraces; however, his other organ functions were preserved. During his time in the Intensive Care Unit (ICU), multiple subspecialist teams participated in his care including physicians, pharmacists, nurses, nutritionists, case management, and social work. The VV ECMO was weaned off after 91 days of support, after which he had a prolonged hospital course due to inflammatory bowel disease, and aspiration pneumonia. CT scan performed six weeks prior to discharge showed mild improvement in diffuse airspace opacities superimposed on extensive chronic cystic changes. He was eventually discharged to a rehabilitation facility 68 days after ECMO removal. He was then seen in our outpatient pulmonary clinic one month and our Post-Intensive Care Syndrome clinic three months after discharge on two liters of nasal cannula oxygen. Pulmonary function testing done at this time demonstrated severe restrictive lung disease and severely reduced diffusion capacity. This case highlights the need for multidisciplinary collaboration among hospital teams to ensure success and patient survival in the setting of COVID ARDS. In those COVID ARDS patients with intact renal, metabolic, hematologic, and cardiovascular function, ECMO should be strongly considered. 2022 AME Case Reports. All rights reserved.

Entities:  

Keywords:  Acute respiratory distress syndrome (ARDS); case report; extracorporeal membrane oxygenation (ECMO); novel coronavirus 2019 (COVID-19)

Year:  2022        PMID: 35128316      PMCID: PMC8762385          DOI: 10.21037/acr-21-51

Source DB:  PubMed          Journal:  AME Case Rep        ISSN: 2523-1995


  14 in total

1.  Long-Term Survival, Posttraumatic Stress, and Quality of Life post Extracorporeal Membrane Oxygenation.

Authors:  Olivia Harley; Claire Reynolds; Priya Nair; Hergen Buscher
Journal:  ASAIO J       Date:  2020-08       Impact factor: 2.872

2.  Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.

Authors:  Giles J Peek; Miranda Mugford; Ravindranath Tiruvoipati; Andrew Wilson; Elizabeth Allen; Mariamma M Thalanany; Clare L Hibbert; Ann Truesdale; Felicity Clemens; Nicola Cooper; Richard K Firmin; Diana Elbourne
Journal:  Lancet       Date:  2009-09-15       Impact factor: 79.321

3.  Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients.

Authors:  Aude Sylvestre; Mélanie Adda; François Maltese; Ariane Lannelongue; Florence Daviet; Gabriel Parzy; Benjamin Coiffard; Antoine Roch; Anderson Loundou; Karine Baumstarck; Laurent Papazian
Journal:  Ann Intensive Care       Date:  2019-07-16       Impact factor: 6.925

4.  VV-ECMO usage in ARDS due to COVID-19: Clinical, practical and ethical considerations.

Authors:  Marguerite M Hoyler; Shreyajit Kumar; Richard Thalappillil; Robert S White; Christopher W Tam
Journal:  J Clin Anesth       Date:  2020-05-20       Impact factor: 9.452

5.  The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome.

Authors:  Matthieu Schmidt; Elie Zogheib; Hadrien Rozé; Xavier Repesse; Guillaume Lebreton; Charles-Edouard Luyt; Jean-Louis Trouillet; Nicolas Bréchot; Ania Nieszkowska; Hervé Dupont; Alexandre Ouattara; Pascal Leprince; Jean Chastre; Alain Combes
Journal:  Intensive Care Med       Date:  2013-08-02       Impact factor: 17.440

6.  The effect of multidisciplinary extracorporeal membrane oxygenation team on clinical outcomes in patients with severe acute respiratory failure.

Authors:  Soo Jin Na; Chi Ryang Chung; Hee Jung Choi; Yang Hyun Cho; Kiick Sung; Jeong Hoon Yang; Gee Young Suh; Kyeongman Jeon
Journal:  Ann Intensive Care       Date:  2018-02-27       Impact factor: 6.925

Review 7.  Acute respiratory failure in COVID-19: is it "typical" ARDS?

Authors:  Xu Li; Xiaochun Ma
Journal:  Crit Care       Date:  2020-05-06       Impact factor: 9.097

8.  Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.

Authors:  Xin Li; Zhen Guo; Bailing Li; Xiaolin Zhang; Rui Tian; Wei Wu; Zhongwei Zhang; Yunfei Lu; Nan Chen; Sean P Clifford; Jiapeng Huang
Journal:  ASAIO J       Date:  2020-05       Impact factor: 2.872

9.  Real estimates of mortality following COVID-19 infection.

Authors:  David Baud; Xiaolong Qi; Karin Nielsen-Saines; Didier Musso; Léo Pomar; Guillaume Favre
Journal:  Lancet Infect Dis       Date:  2020-03-12       Impact factor: 25.071

10.  Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.

Authors:  Ryan P Barbaro; Graeme MacLaren; Philip S Boonstra; Theodore J Iwashyna; Arthur S Slutsky; Eddy Fan; Robert H Bartlett; Joseph E Tonna; Robert Hyslop; Jeffrey J Fanning; Peter T Rycus; Steve J Hyer; Marc M Anders; Cara L Agerstrand; Katarzyna Hryniewicz; Rodrigo Diaz; Roberto Lorusso; Alain Combes; Daniel Brodie
Journal:  Lancet       Date:  2020-09-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.